Skip to main content
. 2022 May 3;36(3):1302–1315. doi: 10.21873/invivo.12831

Table V. PMLBCL studies regarding the comparison of R-CHOP-14 vs. R-CHOP-21.

graphic file with name in_vivo-36-1309-i0001.jpg

graphic file with name in_vivo-36-1310-i0001.jpg

*As approximated by the published survival curves. ASCT: Autologous stem cell transplantation; CMR: complete metabolic response; DS: Deauville score; diff.: difference; EFS: event-free survival; FFP: freedom from progression; HR: hazard ratio; LYSA: Lymphoma Study Association; ND: newly diagnosed; NR: not reported; n: number; pts: patients; OS: overall survival; PET(/CT): positron emission tomography(/computed tomography); PFS: progression-free survival; (R)-ACVBP: (rituximab)-doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisolone; R-CHOEP: rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone; R-CHOP-14 or -21:rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, administered every 14 or 21 days; REAL: Revised European-American Classification of Lymphoid Neoplasms; RT: radiotherapy; WHO: World Health Organization; yrs: years.